

CURRICULUM VITAE

JOSÉ MANUEL PÉREZ GARCÍA

DATOS PERSONALES

NIF: 48489463-N.

Nombre y apellidos: José Manuel Pérez García.

Categoría actual: Médico Especialista en Oncología Médica.

E-mail: josemanuel.perez@quironsalud.es

HISTORIAL ACADEMICO

1. Licenciatura en Medicina y Cirugía:

- Facultad de Medicina.
 - Universidad de Murcia.
 - Calificación: Sobresaliente.
 - 1998-2004.
-
- Matrículas de Honor: 12.
 - Sobresalientes: 14.
 - Notables: 2.
 - Aprobados: 2.

2. Examen Médico Interno Residente:

- Enero 2005.
- Número 50.

3. Especialidad Oncología Médica:

Servicio de Oncología Médica.

Hospital Universitario Vall d'Hebrón.

Barcelona.

Mayo 2005-Mayo 2009.

4. Grado de Doctorado:

- Cursos de Doctorado realizados en la Universidad Autónoma de Barcelona durante 2007-2008 con la calificación de sobresaliente.
- Curso de soporte básico instrumentalizado y desfibrilación externa automática.
- Avances en Oncología Radioterápica.
- Investigación aplicada y traslacional en neoplasias digestivas.
- Diagnóstico y tratamiento de las enfermedad hepáticas.

- Trabajo de Investigación-Suficiencia Investigadora titulado “Estatus del receptor de progesterona como factor predictivo de respuesta completa patológica a la quimioterapia neoadyuvante en pacientes con cáncer de mama” presentado en la convocatoria de Septiembre del curso 2008-2009 con la calificación de excelente.

5. Doctor en Medicina:

- Facultad de Medicina.
- Universidad Autónoma de Barcelona.
- Octubre 2015.
- Tesis doctoral: Implicaciones pronósticas y terapéuticas del receptor del factor de crecimiento fibroblástico en pacientes con cáncer de mama metastásico.
Director: Javier Cortés Castán. Co-Director: Josep María Suriñach Caralt.

- **POSICIÓN ACTUAL Y PREVIAS**

- Abril 2016

Director asistencial.

Director de la Unidad de Ensayos Clínicos.

Instituto Oncológico Baselga.

Hospital Quirón.

Barcelona.

- Abril 2016

Medical Monitor.

MedSIR (Medica Scientia Innovation Research) ARO (Academic Research Organisation).

Barcelona.

- Junio 2009-Marzo 2016

Médico Adjunto de Oncología Médica.

Hospital Universitario Vall d'Hebrón.

Unidad de Cáncer de Mama.

Barcelona.

- Junio 2009-Marzo 2016

Consultor Instituto Oncológico Baselga.

Clínica Quirón.

Barcelona.

- Octubre 2011-Marzo 2012

Consultor Unidad de Cáncer de Mama en Hospital de San Joan de Reus.

- Mayo 2005-Mayo 2009

Médico Interno Residente de Oncología Médica.

Hospital Universitario Vall d'Hebrón.

Barcelona.

IDIOMAS

- Castellano: Hablado y escrito.
- Inglés: Hablado y escrito.
Participante del curso: "English and Communication Skills for Medical Professionals". 2009. Londres.
- Catalán: Hablado.

SOCIEDADES PROFESIONALES

- Socio numerario de la Sociedad Española de Oncología Médica (SEOM).
- Socio numerario del grupo SOLTI (Grupo Académico de Investigación en Cáncer de Mama).
- Socio numerario del grupo GEICAM (Grupo Español de Investigación en Cáncer de Mama).

PUBLICACIONES

Artículos:

1. Capdevila, J., **J. Perez-Garcia**, G. Obiols and J. Tabernero, *Targeted therapies in thyroid cancer*. Target Oncol, 2009. 4(4): p. 275-85.
2. Capdevila, J., F.J Ramos, T. Macarulla, E. Elez, M. Ruiz-Echarri, **J. Perez-Garcia** and J. Tabernero. *Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers*. Curr Opin Oncol, 2009. 21(4): p. 374-80.
3. Carles, J., R. Morales, **J.M Perez**, C. Suarez, J. Rodon and C. Valverde. *Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities*. Eur J Cancer, 2009. 45 Suppl 1: p. 309-17.
4. del Campo, J.M., A. Prat, A. Gil-Moreno, **J. Perez** and M. Parera. *Update on novel therapeutic agents for cervical cancer*. Gynecol Oncol, 2008. 110(3 Suppl 2): p. S72-6.
5. Macarulla, T., J. Capdevila, **J. Perez-Garcia**, F.J Ramos, M.E Elez, B. Markman, M. Ruiz Echarri and J. Tabernero. *New approaches and targets in advanced colorectal cancer*. Eur J Cancer, 2009. 45 Suppl 1: p. 79-88.
6. Markman, B., F. Atzori, **J. Perez-Garcia**, J. Tabernero and J. Baselga. *Status of PI3K inhibition and biomarker development in cancer therapeutics*. Ann Oncol, 2009. 21(4): p. 683-91.
7. **Perez-Garcia, J.**, R. Morales, C.M Valverde, J. Rodon, C. Suarez, M.E Semidey, V. Garcia-Patos, R. Bartralot, M. Serra and J. Carles. *Eccrine porocarcinoma presenting with scrotal lymphedema: a case report and review of systemic treatment*. Ann Oncol, 2009. 21(4): p. 907.
8. Rodon, J., **J. Perez**, and R. Kurzrock. *Combining targeted therapies: practical issues to consider at the bench and bedside*. Oncologist. 2010. 15(1): p. 37-50.
9. Vilar, E., R. Salazar, **J. Perez-Garcia**, J. Cortes, K. Oberg and J. Tabernero. *Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors*. Endocr Relat Cancer, 2007. 14(2): p. 221-32.

10. **Perez-Garcia, J.**, J. Capdevila, T. Macarulla, F.J Ramos, E. Elez, M. Ruiz Echarri and J. Tabernero. *Advances in targeted therapy for metastatic colorectal cancer*. *Therapy*, 2009. 6(3): p. 321-33.
11. Morales-Barrera, R., C. Valverde, J. Rodon, **J. Perez**, X. Maldonado, C. Suarez, E. Trilla and J. Carles. *Bilateral testicular germ cell tumours: a single hospital experience*. *Clin Transl Oncol*, 2010. 12(4): p. 299-302.
12. Cortes, J., C. Saura, M. Bellet, E. Muñoz-Couselo, N. Ramirez-Merino, V. Calvo, **J. Perez** and M. Vidal. *HER2 and hormone receptor-positive breast cancer-blocking the right target*. *Nat Rev Clin Oncol*, 2011. 8(5): p. 307-11.
13. Vilar, E., **J. Perez-Garcia** and J. Tabernero. *Pushing the envelope in the mTOR pathway. The second generation of inhibitors*. *Mol Cancer Ther*, 2011. 10(3): p. 395-403.
14. Scaltriti, M., P.J. Eichhorn, J. Cortes, L. Prudkin, C. Aura, J. Jimenez, S. Chandarlapaty, V. Serra, A. Prat, Y.H Ibrahim, M. Guzman, M. Gili, O. Rodriguez, S. Rodriguez, **J. Perez**, S.R Green, S. Mai, N. Rosen, C. Hudis and J. Baselga. *Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients*. *Proc Natl Acad Sci USA*, 2011. 108(9): p. 3761-66.
15. **Perez-Garcia, J.**, E. Muñoz and J. Cortes. *Role of antiangiogenesis in Triple-Negative Breast Cancer Tumors*. *Cancer and Chemotherapy Reviews*, 2011. 6(1): p. 20-27.
16. Serrano, C., J. Cortes, L. De Mattos-Arruda, M. Bellet, P. Gomez, C. Saura, **J. Perez**, M. Vidal, E. Muñoz-Couselo, M.J Carreras, G. Sanchez-Olle, J. Tabernero, J. Baselga and S. Di Cosimo. *Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors*. *Ann Oncol*, 2012. 23(4): p. 897-902.
17. Cortes, J., V. Calvo, N. Ramirez-Merino, J. O'Shaughnessy, A. Brufsky, N. Robert, M. Vidal, E. Muñoz, **J. Perez**, S. Dawood, C. Saura, S. Di Cosimo, A. González-Martín, M. Bellet, O.E Silva, D. Miles, A. Llombart and J. Baselga. *Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis*. *Ann Oncol*, 2012. 23(5): p. 1130-37.

18. Muñoz-Couselo, E., **J. Perez-Garcia** and J. Cortes. *Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer*. *Onco Targets Ther*, 2011. 4: p. 185-192.
19. **Perez-Garcia, J.**, E. Muñoz-Couselo, V. Ortega and J. Cortes. *The beautiful history of pertuzumab*. *Expert Rev Anticancer Ther*, 2012. 12(6): p. 703-705.
20. **Perez-Garcia, J.** and J. Cortes. *Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?* *Breast Cancer Res*, 2012. 14(1): p. 104.
21. García-García, C., Y.H Ibrahim, V. Serra, M.T Calvo, M. Guzman, J. Grueso, C. Aura, **J. Perez**, K. Jessen, Y. Liu, C. Rommel, J. Tabernero, J. Baselga and M. Scaltriti. *Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy*. *Clin Cancer Res*, 2012. 18(9): p. 2603-2612.
22. Dienstmann, R., D. Serpico, J. Rodon, C. Saura, T. Macarulla, E. Elez, M. Alsina, J. Capdevila, **J. Perez-Garcia**, G. Sanchez-Olle, C. Aura, L. Prudkin, S. Landolfi, J. Hernandez-Losa, A. Vivancos and J. Tabernero. *Molecular profiling of patients with colorectal cancer and matched targeted therapy in Phase 1 clinical trials*. *Mol Cancer Ther*, 2012. 11(9): p. 2062-2071.
23. **Perez-Garcia, J.** and J. Cortes. *A roadmap for accelerated drug approval in breast cancer?* *Lancet Oncol*, 2012. 13(9): p. 850-851.
24. Ibrahim, Y.H., C. García-García, V. Serra, L. He, K. Torres-Lockhart, A. Prat, P. Anton, P. Cozar, M. Guzman, J. Grueso, O. Rodriguez, M.T Calvo, C. Aura, O. Diez, I.T Rubio, **J. Perez**, J. Rodon, J. Cortes, L.W Ellisen, M. Scaltriti and J. Baselga. *PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition*. *Cancer Discov* 2012. 2(11): p. 1036-1047.
25. Oliveira, M., J. Cortés, M. Bellet, J. Balmaña, L. De Mattos-Arruda, P. Gómez, E. Muñoz, V. Ortega, **J. Pérez**, C. Saura, M. Vidal, I.T Rubio and S. Di Cosimo. *Management of the axilla in early breast cancer patients in the genomic era*. *Ann Oncol*, 2012. 24(5): p. 1163-1170.

26. Serra, V., P.J. Eichhorn, C. García-García, Y.H Ibrahim, L. Prudkin, G. Sánchez, O. Rodríguez, P. Antón, J.L Parra, S. Marlow, M. Scaltriti, **J. Perez-Garcia**, A. Prat, J. Arribas, W.C Hahn, S.Y Kim and J. Baselga. *RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer*. J Clin Invest, 2013. 123(6): p. 2551-2563.
27. Andre, F., T. Bachelot, M. Campone, F. Dalenc, **J. Perez-Garcia**, S.A Hurvitz, N.C Turner, H. Rugo, J.W Smith, S. Deudon, M.M Shi, Y. Zhang, A. Kay, D. Graus Porta, A. Yovine and J. Baselga. *Targeting FGFR With Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer*. Clin Cancer Res, 2013. 19(13): p. 3693-3702.
28. **Perez-Garcia, J.**, E. Muñoz-Couselo and J. Cortes. *The effect of biology in the treatment of small breast tumors*. Am Soc Clin Oncol Educ Book, 2013. p. 25-31.
29. **Perez-Garcia, J.** and J. Cortes. *Adjuvant Bevacizumab: positive data from a negative trial*. Lancet Oncol, 2013. 14(10): p. 910-911.
30. **Perez-Garcia, J.**, E. Muñoz-Couselo and J. Cortes. *Bone metastases: Causes, consequences and therapeutic opportunities*. Eur J Cancer, 2013. 11(2): p.254-256.
31. Dienstmann, R., J. Rodon, A. Prat, **J. Perez-Garcia**, B. Adamo, E. Felip, J. Cortes, A.J Iafrate, P. Nuciforo and J. Tabernero. *Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors*. Ann Oncol, 2014. 25(3): p. 552-563.
32. Cortes, J., E. Calvo, A. Vivancos, **J. Perez-Garcia**, J.A Recio and J. Seone. *New approach to cancer therapy based on a molecularly defined cancer classification*. Ca Cancer J Clin, 2014. 64 (1): p. 70-74.
33. Zamora, E., E. Muñoz-Couselo, J. Cortes and **J. Perez-Garcia**. *The fibroblast growth factor receptor: A new potential target for the treatment of breast cancer*. Curr Breast Cancer Rep, 2014. 6 (2): p. 51-58.
34. **Pérez-Garcia, J.**, E. Muñoz-Couselo, J. Cortés and M. Scaltriti. *Therapeutic Antibodies in Breast Cancer*. Semin Oncol, 2014. 41 (5): p. 576-588.
35. Bedard, P.L., J. Tabernero, F.Janku, Z.A Wainberg, L. Paz-Ares, J. Vansteenkiste, E.Van Cutsem, **J. Perez-Garcia**, A. Stathis, C.D Britten, N.T. Le, K. Carter, D. Demanse, D. Csonka, M. Peters, A. Zubel, H. Nauwelaerts and C. Sessa. *A phase Ib dose escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in*

- combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumours. Clin Cancer Res, 2015. 21 (4): p. 730-738.*
36. Bosch, A., Z. Li, A. Bergamaschi, H. Ellis, E. Toska, A. Prat, J.J Tao, D.E Spratt, N.T Viola-Villegas, P. Castel, G. Minuesa, N. Morse, J. Rodón, Y. Ibrahim, J. Cortes, **J. Perez-Garcia**, P. Galvan, J. Grueso, M. Guzman, J.A Katzenellenbogen, M. Kharas, J.S Lewis, M. Dickler, V. Serra, N. Rosen, S. Chandarlapaty, M. Scaltriti and J. Baselga. *PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med, 2015. 7 (283): 283ra51.*
 37. Nuciforo, P., S. Thyparambil, C. Aura, A. Garrido-Castro, M. Vilaro, V. Peg, J. Jimenez, R. Vicario, F. Cecchi, W. Hoos, J. Burrows, T. Hembrough, J.C Ferreres, **J. Perez-Garcia**, J. Arribas, J. Cortes and M. Scaltriti. *High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol, 2016. 10 (1): p. 138-147.*
 38. De Mattos-Arruda, L., G. Bottai, P.G Nuciforo, L. Di Tomasso, E. Giovannetti, V. Peg, A. Losurdo, **J. Perez-Garcia**, G. Masci, F. Corsi, J. Cortes, J. Seoane, G.A Callin and L. Santarpià. *MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget, 2015. 6 (35): p. 37269-37280.*
 39. Muñoz-Couselo, E., J.S Garcia, **J.M Perez-Garcia**, V.O Cebrian and J.C Castan. *Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. Ann Transl Med, 2015. 3 (15): 207.*
 40. Holgado, E., **J.M Perez**, A. Wren, J. Cortes and A. Gomez-Pinillos. *Influencing cancer treatment. Lancet Oncol, 2015. 16 (16): p. 1591-1593.*

41. Diaz-Botero, S., M. Espinosa-Bravo, V.R Gonçalves, A. Esgueva- Colmenarejo, V. Peg, **J. Perez**, J. Cortes and I.T Rubio. *Different Prognostic implications of residual disease after neoadjuvant treatment: impact of Ki67 and site of response*. Ann Surg Oncol, 2016. 23 (12): p. 3831-3837.
42. Nogova, L., L.V Sequist, **J.M Perez Garcia**, F. Andre, J.P Delord, M. Hidalgo, J.H.M Schellens, P.A Cassier, D.R Camidge, M. Schuler, U. Vaishampayan, H. Burris, G.G Tian, M. Campone, Z.A Wainberg, W-T Lim, P. LoRusso, G.I Shapiro, K. Parker, X. Chen, S. Choudhury, F. Ringeisen, D. Graus-Porta, D. Porter, R. Isaacs, R. Buettner and J. Wolf *Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study*. J Clin Oncol, 2017. 35 (2): p. 157-165.
43. Peg, V., I. Sansano I, B. Vieites, L. Bernet, R. Cano, A. Córdoba, M. Sancho, M.D Martín, F. Vilardell, A. Cazorla, M. Espinosa-Bravo, **J.M Pérez-García**, J. Cortés, I.T Rubio and S. Ramón y Cajal. *Role of total tumour load of sentinel lymph node on survival in early breast cancer patients*. Breast, 2017, 33: p. 8-13.
44. Muñoz-Couselo, E., E. Zamora Adelantado, C. Ortiz, J. Soberino Garcia, and **J. Perez-Garcia**. *NRAS-mutant melanoma: current challenges and future prospect*. Onco Targets Ther, 2017. 10: p. 3941-47.
45. de Melo Gagliato, D., J. Cortes, G. Curigliano, S. Loi, C. Denkert, **J. Perez-Garcia** and E. Holgado. *Tumor-infiltrating lymphocytes in breast cancer and implications for clinical practice*. Biochim Biophys Acta, 2017. 1868(2): p. 527-537.
46. Cortés, J., S.A Im, E. Holgado, **J.M Perez-Garcia**, P. Schmid and M. Chavez-MacGregor. M. *The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies*. Cancer Treat Rev, 2017. 61: p. 53-60.
47. **Perez-Garcia, J.** and J. Cortes. *Breast cancer in 2017: Spurring science, marking progress, and influencing history*. Nat Rev Clin Oncol, 2018. 15(2): p. 79-80.

48. Cortes, J., **J. Perez-Garcia**, C Levy, P Gómez Pardo, H Bourgeois, S Spazzapan, N Martínez-Jañez, T.C Chao, M. Espié, J.M Nabholz, X. González Farré, V. Beliakouski, J Román García, E. Holgado and M. Campone. *Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer*. Ann Oncol, 2018. Epub Ahead of Print.

Comunicaciones a congresos:

1. Análisis de la precisión de la historia familiar (HF) en pacientes diagnosticados de cáncer de mama (CM) o de colon (CCR). SEOM 2007. Madrid.
2. Progesterone receptor negativity predicts pathological complete response after neoadjuvant chemotherapy in breast cancer patients. ESMO IMPAKT 2009. Bruselas.
3. Role of progesterone receptor status as predictive factor of pathological complete response to neoadjuvant chemotherapy in breast cancer patients. ASCO 2009. Orlando.
4. Cardiotoxicidad asociada a doxorrubicina liposomal no pegilada en pacientes con cáncer de mama metastásico previamente tratado con antraciclinas. SEOM 2009. Barcelona.
5. Trastuzumab-related cardiotoxicity in the elderly: which role for cardiovascular risk factors? ECCO 2009. Berlín.
6. Bilateral testicular germ cell tumors: a single hospital experience. ECCO 2009. Berlín.
7. Adjuvant Docetaxel and Cyclofosfamide in breast cancer patients over 65 years: compliance and toxicity. ECCO 2009. Berlín.
8. Clinical experience with Cetuximab and Paclitaxel combination in metastatic/recurrent squamous cell cancer carcinoma of the head and neck (SCCHN) – retrospective analysis of a single institution. ECCO 2009. Berlín.
9. Role of progesterone receptor status as predictive factor of pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. ASCO 2010. Chicago.
10. Low cardiotoxicity of non-pegylated liposomal doxorubicin in patients with metastatic breast cancer previously exposed to 360 mg/m² of doxorubicin. ASCO 2010. Chicago.
11. Risk of gastrointestinal perforation in patients with metastatic breast cancer treated with Bevacizumab: a meta-analysis. ASCO 2010. Chicago.
12. Implication of breast cancer phenotype in patients with leptomeningeal carcinomatosis. ESMO 2010. Milan.

13. Does obesity hamper response to Trastuzumab in post-menopausal patients with metastatic breast cancer? ESMO 2010. Milan.
14. PI3KCA mutation status in a cohort of patients suitable for phase I trials with specific targeted agents. Medical Genome Sequencing: Understanding the Genomes of Disease. 2010. Barcelona.
15. Body mass index as a predictive factor of pathological complete response to neoadjuvant chemotherapy in breast cancer patients. SABCS 2010. San Antonio.
16. Predictive factors of complete axillary downstaging after neoadjuvant chemotherapy in breast cancer patients. SABCS 2010. San Antonio.
17. Combined PI3K and MEK inhibition in patient-derived xenografts generated from recurrent triple negative breast cancer. AACR 2011. Orlando.
18. Clinical risk factors as predictors of potential cardiotoxicity related to nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer (MBC) patients (pts) previously treated with conventional anthracyclines (D). ASCO 2011. Chicago.
19. Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple negative breast cancer (mTNBC). ASCO 2011. Chicago.
20. Evaluation of overall survival (OS) in patients (pts) with metastatic breast cancer (MBC) according to phosphatidylinositol-3-kinase (PI3K) pathway status. ASCO 2011. Chicago.
21. A multicenter, open-label phase 2 trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. ASCO 2011. Chicago.
22. A multicenter, open-label phase 2 trial of dovitinib, a fibroblast growth factor receptor 1 (FGFR1) inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer (BC). ASCO Breast Cancer Symposium 2011. San Francisco.
23. Survival Outcome with Bevacizumab: Activation of the Phosphatidylinositol-3 Kinase (PI3K) Pathway Due to PIK3CA Mutations or PTEN Loss Makes a Difference. SABCS 2011. San Antonio.
24. Breast Cancer Subtype and Survival in Metastatic Patients Treated With Bevacizumab. ECCO 2011. Estocolmo.

25. Personalized therapy of colorectal cancer patients enrolled in Phase 1 trials with targeted agents based on molecular profiling of tumors. TAT 2012. Amsterdam.
26. PI3K pathway inhibitors: How deep should we go? TAT 2012. Amsterdam.
27. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. AACR 2012. Chicago.
28. Antitumor activity of lapatinib in combination with the dual mTORC1/2 inhibitor INK-128 in breast tumors resistant to anti-HER2 therapy. AACR 2012. Chicago.
29. A phase Ib, open-label, multi-center, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. ASCO 2012. Chicago.
30. Molecular profiling of patients (pts) with colorectal cancer (CRC) and matched targeted therapy (MTA) in phase 1 clinical trials. ASCO 2012. Chicago.
31. Prognostic significance of PI3K pathway (PI3Kp) dysregulation in a metastatic breast cancer (MBC) population. ASCO 2012. Chicago.
32. Presentation and treatment of HER2 positive metastatic breast cancer patients already treated with adjuvant trastuzumab. ASCO 2012. Chicago.
33. PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts). ASCO 2012. Chicago.
34. Mass Spectrometry Based Quantitative Analysis of the HER Family Receptors in FFPE Breast Cancer Tissue. SABCS 2012. San Antonio.
35. Symptomatic Bone Marrow Involvement (BMinv) in Breast Cancer (BC): Clinical Presentation, Treatment and Prognosis According To BC Subtype and Zoledronic Acid (ZA) Use. A Single Institution Review. SABCS 2012. San Antonio.
36. Phase Ib study of oral pan-PI3K BKM120 (buparlisib) in combination with the oral MEK1/2 inhibitor GSK1120212 (trametinib) in patients with selected advanced solid tumors and RAS/RAF mutations. ECCO 2013. Amsterdam.
37. APHINITY (BIG4-11/BO25126/TOC4939G/GEICAM201011/SOLT11006): Estudio fase III, randomizado, doble ciego, controlado con placebo que compara QT + trastuzumab + placebo vs QT + trastuzumab + pertuzumab, como tratamiento

- adyuvante en pacientes con cáncer de mama operable HER2+. SEOM 2013. Salamanca.
38. PI3K blockade enhances the antitumor activity of eribulin in *PIK3CA*-mutant eribulin-resistant tumor xenografts. SABCS 2013. San Antonio.
 39. Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy. ASCO 2014. Chicago.
 40. PI3K and MEK inhibitor combination toxicities and relative dose intensity: Vall d'Hebron experience. EORTC-NCI-AACR 2014. Barcelona.
 41. Quantitative measurement of HER2 levels by multiplexed mass spectrometry from FFPE tissue predicts survival in patients treated with anti-HER2 based therapy. SABCS 2014. San Antonio.
 42. Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. SABCS 2014. San Antonio.
 43. Complete axillary response in breast cancer patients after neoadjuvant treatment correlates with overall survival. SSO 2015. Houston.
 44. Neoadjuvant therapy in HER2+ breast cancer: Opti-Her Heart run-in phase safety data (SOLTI-1002). Sant Gallen 2015. Vienna.
 45. Early drug development in advanced gynecologic cancer based on genetic tumor profiling. ASCO 2015. Chicago.
 46. HER2 quantification by mass spectrometry is superior to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC). ASCO 2015. Chicago.
 47. Integrating multiplex and next generation sequencing (NGS) platforms in routine molecular profiling of metastatic breast cancer (MBC) patients (pts): Trends for enrollment in genotype-directed clinical trials (GDTs). SABCS 2015. San Antonio.
 48. Concordance in fibroblast growth factor receptor 1 (FGFR1) and 2 (FGFR2) status in breast cancer during tumor progression. SABCS 2015. San Antonio.
 49. PARP 1 / 2 inhibition in a subset of triple negative breast cancer (TNBC) patient-derived tumor xenografts (PDX) identifies predictive biomarkers of response. SABCS 2015. San Antonio.

50. Analysis of total tumor load of sentinel lymph node as a prognostic factor in early breast cancer patients. ASCO 2016. Chicago.
51. Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC). ASCO 2016. Chicago.
52. Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in metastatic breast cancer (MBC) patients (pts). ASCO 2016. Chicago.
53. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors. ASCO 2016. Chicago.
54. The Next Era of Treatment for HR+/HER2- Advanced Breast Cancer: Clinical Trials of Triplets Combinations. CoBrCA 2016. Barcelona.
55. Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer - Final results of the SOLTI OPTI-HER HEART study. SABCS 2016. San Antonio.
56. PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007). SABCS 2016. San Antonio.
57. Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study). SABCS 2016. San Antonio.
58. The next era of treatment for HR+/HER2- advanced breast cancer: clinical trials of endocrine therapy + CDK4/6 inhibitor + PI3K/AKT/mTOR inhibitor triplet combinations. Miami Breast Cancer Conference 2017. Miami.
59. Molecular markers to predict response to selective fibroblast growth factor receptor inhibitors (FGFRinh) in patients (pts) with FGFR-amplified (amp) or mutated (mut) tumors. ASCO 2017. Chicago.
60. Subtipos intrínsecos como factor predictivo de respuesta completa patológica (RCp) tras tratamiento neoadyuvante de cáncer de mama HER2-positivo con quimioterapia y bloqueo dual con trastuzumab y pertuzumab. Estudio OPTI-HER-HEART (OHH). SEOM 2017. Madrid.

61. Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer. SABCS 2017. San Antonio.
62. Chemotherapy-free trastuzumab and pertuzumab in HER2 [+] breast cancer: FDG-PET response-adapted strategy. The PHERGain study. SABCS 2017. San Antonio.

Libros:

1. Libro: Ácido Zoledrónico. Evidencia y Experiencia. Editorial Permanyer. 2011. ISBN colección: 978-84-9926-199-7. ISBN: 978-84-9926-309-0.
2. Capítulo del libro: Manual de práctica clínica en senología (2ª Edición). Tratamiento hormonal adyuvante del cáncer de mama. Pacientes pre o perimenopáusicas. Sociedad Española de Senología y Patología Mamaria. 2012. ISBN: 978-84-695-6593-3.
3. Capítulo del libro: Manual de práctica clínica en senología (2ª Edición). Tratamiento hormonal adyuvante del cáncer de mama. Pacientes postmenopáusicas. Sociedad Española de Senología y Patología Mamaria. 2012. ISBN: 978-84-695-6593-3.
4. Libro: Comprender el cáncer de mama. Editorial Profit. 2013. ISBN: 978-84-9735-685-5.
5. Capítulo del libro: Tecnología Nab en Medicina. Papel de los taxanos en cáncer de mama metastásico. Transworld Editors. 2013. ISBN: 978-84-941494-0-5.
6. Capítulo del libro: Manual de manejo de Lapatinib. Perfil de seguridad: Actividad en los estudios publicados en las indicaciones aprobadas. InScience Communications. 2013.
7. Capítulo del libro: Manejo quirúrgico y anatomopatológico del cáncer de mama. Papel de la neoadyuvancia en cáncer de mama. 2015. ISBN 978-84-941494-3-6.
8. Capítulo del libro: Tecnología Nab en Medicina (2ª edición). Papel de los taxanos en cáncer de mama metastásico. Transworld Editors. 2016. ISBN: 978-84-941494-5-0.

PROYECTOS Y BECAS

1. Beca FIS. Desvelando las vías moleculares que llevan al desarrollo de la carcinomatosis leptomeningea.

ASISTENCIA A CONGRESOS, CURSOS, Y SYMPOSIUMS

1. III Curso de Formación SEOM en Cuidados Continuos. 2005. Valencia.
2. Global Expert Meeting – Gateway to advancing anemia management. 2007. Hamburgo.
3. Curso de Soporte Vital Básico Instrumentalizado y Desfibrilación Externa Automática. 2007. Barcelona.
4. European Society of Medical Oncology Congress. 2008. Estocolmo.
5. Investigación Aplicada y Traslacional en Neoplasias Digestivas. 2008. Barcelona.
6. PDX-011 Study Coordinator´s Meeting. 2008. Niza.
7. American Society of Clinical Oncology Congress. 2009. Orlando.
8. San Antonio Breast Cancer Symposium. 2009. San Antonio.
9. Innovators in Breast Cancer (UK). 2009. Birmingham.
10. IMPAKT Breast Cancer Conference. 2009. Bruselas.
11. Curso SAP de consultas externas/gabinetes para médicos. 2009. Barcelona.
12. Curso SAP de hospitalización y hospitalización a domicilio para médicos. 2009. Barcelona.
13. Curso SAP de hospital de día para médicos. 2009. Barcelona.
14. Curso SAP de formación de formadores de navegación SAP y ETC. 2009. Barcelona.
15. European Breast Cancer Conference. 2010. Barcelona.
16. Expert Practice in Breast Cancer. 2010. Atenas.
17. American Society of Clinical Oncology Congress. 2010. Chicago.
18. Advance Course on Breast Cancer Management. 2010. Roma.
19. European Society of Medical Oncology Congress. 2010. Milan.
20. XI Jornadas de Revisión de ASCO. 2011. Barcelona.
21. XII Jornadas de Revisión de ASCO. 2012. Barcelona.
22. 2º Simposio Nacional SEOM. 2012. Madrid.
23. 17thFritz-Bender-Foundation International Symposium: Progress Towards Individualized Cancer Treatments. 2013. Barcelona.
24. 1st European Think Tank Meeting on Breast Cancer. 2013. Barcelona.
25. American Society of Clinical Oncology Congress. 2015. Chicago.

26. XVI Jornadas de Revisión de ASCO. 2016. Barcelona.
27. Barcelona Breast Cancer Meeting (BBCM). 2016. Barcelona.
28. Controversies in Breast Cancer (CoBrCa). 2016. Barcelona.
29. Breast Cancer Academy. 2016. Bruselas.
30. San Antonio Breast Cancer Symposium. 2016. San Antonio.
31. Breast Cancer Academy. 2017. Paris.
32. Barcelona Breast Cancer Meeting (BBCM). 2017. Barcelona.
33. American Society of Clinical Oncology Congress. 2017. Chicago.
34. European Society of Medical Oncology Congress. 2017. Madrid.

PONENTE EN CONGRESOS, CURSOS, Y SYMPOSIUMS

1. Curso Anticuerpos Monoclonales en Cáncer de Mama. Optimizando estudios clínicos y sus resultados. Ponencia 1: Análisis de biopsias en pacientes con cáncer de mama metastásico. Ponencia 2: ¿Debemos tratar a las pacientes HER2-positivas y tumores pT1a y pT1b con trastuzumab? 2010. Barcelona.
2. Curso Anticuerpos Monoclonales en Cáncer de Mama. Optimizando estudios clínicos y sus resultados. Ponencia 1: Análisis de biopsias en pacientes con cáncer de mama metastásico. Ponencia 2: Eficacia de bevacizumab en pacientes triple negativo. 2011. Barcelona.
3. Curso Anticuerpos Monoclonales en Cáncer de Mama. Optimizando estudios clínicos y sus resultados. Ponencia 1: Análisis de biopsias en pacientes con cáncer de mama metastásico. Ponencia 2: Eficacia de bevacizumab en pacientes triple negativo. 2012. Barcelona.
4. 2º Simposio Nacional SEOM. Ponencia: Highlights 2º Simposio Nacional SEOM. 2012. Madrid.
5. Curso Medical Education Program on Breast Cancer Management. Ponencia: Pertuzumab en cáncer de mama metastásico. 2013. Barcelona.
6. XVI Reunión de Consenso en Tratamiento Oncológico: Cáncer de Mama. Ponencia: Tratamiento de la enfermedad avanzada en tumores HER2-positivos. 2013. Córdoba.

7. XIII Jornadas de Revisión de ASCO. Ponencia: Mama diseminada. 2013. Barcelona.
8. XIII Jornadas de Revisión de ASCO. Ponencia: Mama diseminada. 2013. Madrid.
9. Curso Preceptorship Breast Cancer. Ponencia: Discusión de casos clínicos. 2013. Barcelona.
10. Curso pre-symposium internacional Dexeus. Biología molecular del cáncer de origen ginecológico. Ponencia: Update on clinical development for Luminal B tumors. 2013. Barcelona.
11. Curso Preceptorship Breast Cancer: Ponencia: Discusión de casos clínicos. 2015. Barcelona.
12. Curso HER2+ Breast Cancer Challenges and Unanswered Questions: Ponencia: Discusión de casos clínicos. 2015. Barcelona.
13. Curso La Oncología Médica en 3 Días. Ponencia: Neoadyuvancia en cáncer de mama HER2-positivo. 2016. Madrid.
14. Curso Medical Education Program on Breast Cancer Management. Ponencias: HER2 retesting; Tumores pT1b; Doble o mono bloqueo en neoadyuvancia. 2016. Madrid.